What did BioArctic announce about Leqembi sales projections?

BioArctic said its partner Eisai presented a financial simulation projecting global sales of Leqembi to reach around JPY 300 billion by fiscal year 2028, ending March 2029. That is roughly equivalent to SEK 17.6 billion. The projection reflects expectations for wider patient adoption of the Alzheimer’s treatment over the next several years.

What is Leqembi and why is it important for BioArctic?

Leqembi is an Alzheimer’s disease treatment developed by BioArctic and Eisai that targets amyloid-beta in the brain. The drug is designed to slow disease progression in adults with early Alzheimer’s disease. For BioArctic, Leqembi is strategically important because the company receives royalties and milestone payments tied to global sales.

Why are investors paying attention to Eisai’s JPY 300 billion sales forecast for Leqembi?

The forecast gives investors a clearer picture of the potential commercial scale of Leqembi over the medium term. If sales approach those levels, BioArctic could benefit materially through royalty income and milestone payments without carrying the full commercialization burden globally. However, the projection is still a simulation, not guaranteed future revenue.

How widely approved is Leqembi right now?

Leqembi is currently approved in 53 countries for treating early Alzheimer’s disease. Regulatory reviews are also ongoing in six additional jurisdictions. Expanding geographic approvals are important because broader market access increases the pool of eligible patients and potential revenue generation.

Why has Leqembi adoption been relatively gradual so far?

The rollout has been slower partly because Alzheimer’s treatments often face logistical and healthcare-system bottlenecks. Diagnosis pathways, infusion infrastructure, patient monitoring requirements, and physician adoption can all slow uptake. BioArctic and Eisai believe easier treatment formats could help accelerate adoption in coming years.

Image for illustrative purposes only. Not a real photo.

Eisai models ¥300 billion in potential Leqembi sales for fiscal year 2028

Written by Brie CarterPublished May. 26 2026Last Updated May. 25 2026

BioArctic announced that its long-term development and commercialization partner, Eisai, has presented an updated financial simulation outlining the growth trajectory for their co-developed Alzheimer’s disease treatment, Leqembi (lecanemab).

During its Investor Relations Day presentation, Eisai disclosed a model indicating that global sales of the amyloid-beta directing monoclonal antibody are simulated to reach approximately JPY 300 billion (equivalent to roughly SEK 17.6 billion) for fiscal year 2028.

The fiscal period finishes at the end of March 2029.

BioArctic issued the market notification in compliance with disclosure requirements mandated under the EU Market Abuse Regulation framework.

The modeled multi-year revenue target reflects an anticipated acceleration in patient adoption curves, following a historically measured roll-out since Leqembi's initial regulatory entries in 2023.

The pharmaceutical partners are banking on structural transformations in the clinical pathway to clear treatment bottlenecks.

Growth models are heavily leveraged against the global expansion of more accessible treatment formulations, including subcutaneous auto-injectors currently under priority regulatory review in major markets.

Leqembi is presently approved in 53 countries to slow disease progression in adults navigating early Alzheimer's disease, with formal regulatory reviews ongoing in six additional jurisdictions.

Under the terms of the baseline strategic research alliance between the two companies, BioArctic retains rights to commercialize the biologic in the Nordic region while remaining entitled to milestone payments and tiered royalties on global sales executed by Eisai.